Progyny (PGNY) EBITDA (2018 - 2026)

Progyny (PGNY) has reported EBITDA for 9 consecutive years, with $40.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 64.23% year-over-year to $40.0 million in Q2 2026; TTM through Jun 2026 was $112.1 million, a 46.06% increase from a year earlier, with the FY2025 full-year figure at $85.3 million, up 26.42% from the prior year.
• EBITDA was $40.0 million for Q2 2026 at Progyny, up from $35.4 million in the prior quarter.
• Over five years, EBITDA peaked at $40.0 million in Q2 2026 and troughed at -$58000.0 in Q1 2022.
• A 5-year average of $17.4 million and a median of $15.5 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 100.49% in 2022 and jumped 25981.03% in 2023, its largest moves.
• Over 5 years, EBITDA stood at $3.3 million in 2022, then surged by 317.42% to $13.8 million in 2023, then rose by 14.4% to $15.8 million in 2024, then slipped by 3.58% to $15.2 million in 2025, then jumped by 162.8% to $40.0 million in 2026.
• The last three EBITDA figures came in at $40.0 million (Q2 2026), $35.4 million (Q1 2026), and $15.2 million (Q4 2025), per Business Quant data.